Kazia TherapeuticsTrust (KZIA): Several Upcoming Catalysts
Kazia Therapeutics announces progress in its pivotal GBM AGILE study for lead asset paxalisib, with data expected in CY23. Recent US C-suite appointments indicate a focus on commercialization. The second asset, EVT801, is in human trials, with the first patient enrolled in France. The company's valuation has increased to US$294m or US$22.28 per basic ADR, driven by NPV roll-forward, despite lower cash and higher R&D costs. Net cash stood at US$11.0m as of December 31, 2021, indicating a runway into H123.
- Increased valuation to US$294m or US$22.28 per basic ADR.
- Paxalisib data expected in CY23, with potential regulatory filing.
- Progress in EVT801 human trials, first patient enrolled.
- Lower net cash reported at US$11.0m as of December 31, 2021.
- Higher R&D estimates impacting financial outlook.
LONDON, UK / ACCESSWIRE / March 30, 2022 / Patient recruitment in the pivotal GBM AGILE study for lead asset paxalisib remains on track, with data expected in CY23, to be followed by a potential regulatory filing, if data are positive. Recent C-suite appointments in the United States suggest an increased focus on commercialization, particularly in the US market. Second asset EVT801 has progressed to human studies, with the first patient enrolled in a Phase I trial in France in November 2021 and interim data expected in H2 CY22. We expect CY22 to be catalyst rich, with data anticipated from multiple investigator-sponsored studies evaluating paxalisib in the treatment of brain metastases (BMs), as well as pediatric brain cancers such as diffuse intrinsic pontine glioma (DIPG). Positive readouts from any study alone could potentially trigger a re-rating for the stock. We have increased our valuation to US
Our valuation increases to US
Click here to view the full report or here to sign up to receive research as it is published.
All reports published by Edison are available to download free of charge from its website
About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.
Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
For more information, please contact Edison:
Jyoti Prakash +91 981 880 393 healthcare@edisongroup.com
Learn more at www.edisongroup.com and connect with Edison on:
LinkedIn: www.linkedin.com/company/edison-group-/
Twitter: www.twitter.com/Edison_Inv_Res
YouTube: www.youtube.com/edisonitv
SOURCE: Edison Investment Research Limited
View source version on accesswire.com:
https://www.accesswire.com/695232/Kazia-TherapeuticsTrust-KZIA-Several-Upcoming-Catalysts
FAQ
What is the latest update on Kazia Therapeutics' KZIA stock regarding the GBM AGILE study?
How has Kazia's valuation changed recently?
What are the prospects for EVT801 in Kazia Therapeutics?
What is Kazia's current cash position?
What financial changes has Kazia announced for CY22?
